autologous CD19 CAR-expressing T cells YTB323

A preparation of autologous T lymphocytes that are genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunostimulating and antineoplastic activities. Upon intravenous administration, the autologous CD19 CAR-expressing T cells YTB323 are directed to and induce selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.